TY - JOUR
T1 - Medication underuse during long-term follow-up in patients with peripheral arterial disease
AU - Hoeks, Sanne E
AU - Scholte op Reimer, Wilma J M
AU - van Gestel, Yvette R B M
AU - Schouten, Olaf
AU - Lenzen, Mattie J
AU - Flu, Willem-Jan
AU - van Kuijk, Jan-Peter
AU - Latour, Corine
AU - Bax, Jeroen J
AU - van Urk, Hero
AU - Poldermans, Don
PY - 2009/7
Y1 - 2009/7
N2 - BACKGROUND: Patients with peripheral arterial disease constitute a high-risk population. Guideline-recommended medical therapy use is therefore of utmost importance. The aims of our study were to establish the patterns of guideline-recommended medication use in patients with PAD at the time of vascular surgery and after 3 years of follow up, and to evaluate the effect of these therapies on long-term mortality in this patient group.METHODS AND RESULTS: Data on 711 consecutive patients with peripheral arterial disease undergoing vascular surgery were collected from 11 hospitals in the Netherlands (enrollment between May and December 2004). After 3.1+/-0.1 years of follow-up, information on medication use was obtained by a questionnaire (n=465; 84% response rate among survivors). Guideline-recommended medical therapy use for the combination of aspirin and statins in all patients and beta-blockers in patients with ischemic heart disease was 41% in the perioperative period. The use of perioperative evidence-based medication was associated with a reduction of 3-year mortality after adjustment for clinical characteristics (hazard ratio, 0.65; 95% CI, 0.45 to 0.94). After 3 years of follow-up, aspirin was used in 74%, statins in 69%, and beta-blockers in 54% of the patients respectively. Guideline-recommended medical therapy use for the combination of aspirin, statins, and beta-blockers was 50%.CONCLUSIONS: The use of guideline recommended therapies in the perioperative period was associated with reduction in long-term mortality in patients with peripheral arterial disease. However, the proportion of patients receiving these evidence-based treatments-both at baseline and 3 years after vascular surgery-was lower than expected based on the current guidelines. These data highlight a clear opportunity to improve the quality of care in this high-risk group of patients.
AB - BACKGROUND: Patients with peripheral arterial disease constitute a high-risk population. Guideline-recommended medical therapy use is therefore of utmost importance. The aims of our study were to establish the patterns of guideline-recommended medication use in patients with PAD at the time of vascular surgery and after 3 years of follow up, and to evaluate the effect of these therapies on long-term mortality in this patient group.METHODS AND RESULTS: Data on 711 consecutive patients with peripheral arterial disease undergoing vascular surgery were collected from 11 hospitals in the Netherlands (enrollment between May and December 2004). After 3.1+/-0.1 years of follow-up, information on medication use was obtained by a questionnaire (n=465; 84% response rate among survivors). Guideline-recommended medical therapy use for the combination of aspirin and statins in all patients and beta-blockers in patients with ischemic heart disease was 41% in the perioperative period. The use of perioperative evidence-based medication was associated with a reduction of 3-year mortality after adjustment for clinical characteristics (hazard ratio, 0.65; 95% CI, 0.45 to 0.94). After 3 years of follow-up, aspirin was used in 74%, statins in 69%, and beta-blockers in 54% of the patients respectively. Guideline-recommended medical therapy use for the combination of aspirin, statins, and beta-blockers was 50%.CONCLUSIONS: The use of guideline recommended therapies in the perioperative period was associated with reduction in long-term mortality in patients with peripheral arterial disease. However, the proportion of patients receiving these evidence-based treatments-both at baseline and 3 years after vascular surgery-was lower than expected based on the current guidelines. These data highlight a clear opportunity to improve the quality of care in this high-risk group of patients.
KW - Adrenergic beta-Antagonists/therapeutic use
KW - Aged
KW - Aspirin/therapeutic use
KW - Cardiovascular Agents/therapeutic use
KW - Drug Therapy, Combination
KW - Evidence-Based Medicine/statistics & numerical data
KW - Female
KW - Follow-Up Studies
KW - Guideline Adherence/statistics & numerical data
KW - Humans
KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - Male
KW - Middle Aged
KW - Myocardial Ischemia/drug therapy
KW - Peripheral Vascular Diseases/drug therapy
KW - Platelet Aggregation Inhibitors/therapeutic use
KW - Practice Guidelines as Topic
KW - Prognosis
KW - Registries
KW - Risk Factors
U2 - 10.1161/CIRCOUTCOMES.109.868505
DO - 10.1161/CIRCOUTCOMES.109.868505
M3 - Article
C2 - 20031859
SN - 1941-7713
VL - 2
SP - 338
EP - 343
JO - Circulation. Cardiovascular quality and outcomes
JF - Circulation. Cardiovascular quality and outcomes
IS - 4
ER -